{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:35:12Z","timestamp":1789767312822,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["G015321N"],"award-info":[{"award-number":["G015321N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.metabol.2024.156128","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:12:12Z","timestamp":1735557132000},"page":"156128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["PPAR\u03b1-ERR\u03b1 crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression"],"prefix":"10.1016","volume":"164","author":[{"given":"Milton Boaheng","family":"Antwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Lefere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Koorneef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneleen","family":"Heldens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Onghena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylian","family":"Decroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Fijalkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Thommis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Hellemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hoorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Devisscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"De Bosscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.156128_bb0005","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156128_bb0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156128_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156128_bb0020","article-title":"An updated overview on hepatocellular carcinoma in patients with metabolic dysfunction-associated Steatotic liver disease: trends, pathophysiology and risk-based surveillance","volume":"156080","author":"Armandi","year":"2024","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2024.156128_bb0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/metabo12030238","article-title":"Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH","volume":"12","author":"Welch","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.metabol.2024.156128_bb0030","article-title":"Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease","volume":"3;2(1):13","author":"Antwi","year":"2024","journal-title":"npj Metabolic Health and Disease"},{"issue":"9","key":"10.1016\/j.metabol.2024.156128_bb0035","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1136\/gutjnl-2023-331741","article-title":"Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease","volume":"73","author":"Dubois","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156128_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2024.156128_bb0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156128_bb0050","doi-asserted-by":"crossref","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. Vol. 62, J Hepatology. 2015.p.720\u201333.","DOI":"10.1016\/j.jhep.2014.10.039"},{"issue":"1","key":"10.1016\/j.metabol.2024.156128_bb0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARa gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2024.156128_bb0060","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.metabol.2024.156128_bb0065","article-title":"Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.metabol.2024.156128_bb0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fendo.2019.00206","article-title":"ERR\u03b1 as a bridge between transcription and function: role in liver metabolism and disease","volume":"10","author":"Xia","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.metabol.2024.156128_bb0075","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1210\/en.2018-00115","article-title":"Divergent role of estrogen-related receptor a in lipid-and fasting-induced hepatic steatosis in mice","volume":"159","author":"B\u2019chir","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2024.156128_bb0080","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.ajpath.2021.04.007","article-title":"Inhibition of estrogen-related receptor α blocks liver steatosis and steatohepatitis and attenuates triglyceride biosynthesis","volume":"191","author":"Chen","year":"2021","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156128_bb0085","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/jm101063h","article-title":"Identification of diaryl ether-based ligands for estrogen-related receptor \u03b1 as potential antidiabetic agents","volume":"54","author":"Patch","year":"2011","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.metabol.2024.156128_bb0090","doi-asserted-by":"crossref","first-page":"10874","DOI":"10.7150\/thno.47037","article-title":"Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD\/NASH development","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"issue":"84","key":"10.1016\/j.metabol.2024.156128_bb0095","article-title":"Crosstalk interactions between transcription factors ERR\u03b1 and PPAR\u03b1 assist PPAR\u03b1-mediated gene expression","volume":"15","author":"Desmet","year":"2024","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2024.156128_bb0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jhep.2020.04.011","article-title":"Animal models for liver disease \u2013 a practical approach for translational research","volume":"73","author":"Nevzorova","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156128_bb0105","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.30294","article-title":"Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease","volume":"69","author":"Lefere","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.metabol.2024.156128_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071667","article-title":"Clinically relevant dose of Pemafibrate (SPPARM\u03b1) lowers serum triglyceride levels by targeting hepatic PPAR\u03b1 in mice","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.metabol.2024.156128_bb0115","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156128_bb0120","first-page":"349","volume":"68, Hepatology","author":"Younossi","year":"2018","journal-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis"},{"issue":"7","key":"10.1016\/j.metabol.2024.156128_bb0125","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nature Methods"},{"issue":"11","key":"10.1016\/j.metabol.2024.156128_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293526","article-title":"Liver sinusoidal endothelial cells show reduced scavenger function, and downregulation of fc gamma receptor IIb, yet maintain a preserved fenestration in the Glmpgt\/gt mouse model of slowly progressing liver fibrosis","volume":"18","author":"Antwi","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2024.156128_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109174","article-title":"Role of liquid fructose\/sucrose in regulating the hepatic transcriptome in a high-fat Western diet model of NAFLD","volume":"112","author":"Luo","year":"2023","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.metabol.2024.156128_bb0140","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41374-018-0074-z","article-title":"Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water","volume":"98","author":"Liu","year":"2018","journal-title":"Lab Investig"},{"issue":"10","key":"10.1016\/j.metabol.2024.156128_bb0145","doi-asserted-by":"crossref","DOI":"10.1210\/me.2004-0539","article-title":"A nuclear receptor atlas: 3T3-L1 adipogenesis","volume":"19","author":"Fu","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.metabol.2024.156128_bb0150","doi-asserted-by":"crossref","unstructured":"Flessa CM, Nasiri-Ansari N, Kyrou I, Leca BM, Lianou M, Chatzigeorgiou A, et al. Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research. Vol. 23, International Journal of Molecular Sciences. 2022.p.15791.","DOI":"10.3390\/ijms232415791"},{"issue":"3","key":"10.1016\/j.metabol.2024.156128_bb0155","doi-asserted-by":"crossref","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"Fujii","year":"2013","journal-title":"Med Mol Morphol"},{"issue":"2","key":"10.1016\/j.metabol.2024.156128_bb0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11883-020-00901-4","article-title":"High-density lipoproteins and serum amyloid a (SAA)","volume":"23","author":"Webb","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.metabol.2024.156128_bb0165","first-page":"59","article-title":"Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-\u03baB signaling pathway","author":"Jiang","year":"2022","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2024.156128_bb0170","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.metabol.2024.156128_bb0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/toxsci\/kfab068","article-title":"Species differences between mouse and human PPAR\u03b1 in modulating the Hepatocarcinogenic effects of perinatal exposure to a high-affinity human PPAR\u03b1 agonist in mice","volume":"183","author":"Foreman","year":"2021","journal-title":"Toxicol Sci"},{"issue":"47","key":"10.1016\/j.metabol.2024.156128_bb0180","doi-asserted-by":"crossref","first-page":"49330","DOI":"10.1074\/jbc.M407999200","article-title":"Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor \u03b1","volume":"279","author":"Kallen","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156128_bb0185","doi-asserted-by":"crossref","unstructured":"Xia H, Dufour CR, Medkour Y, Scholtes C, Chen Y, Guluzian C, et al. Hepatocyte FBXW7-dependent activity of nutrient-sensing nuclear receptors controls systemic energy homeostasis and NASH progression in male mice. Nature Communications . 2023;14:6982.","DOI":"10.1038\/s41467-023-42785-3"},{"issue":"10","key":"10.1016\/j.metabol.2024.156128_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/gut.2010.222844","article-title":"Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C","volume":"60","author":"Miquilena-Colina","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156128_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155914","article-title":"O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36","volume":"156","author":"Zhu","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156128_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2016.12.013","article-title":"Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice","volume":"69","author":"Honda","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156128_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154220","article-title":"Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model","volume":"107","author":"Van Campenhout","year":"2020","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2024.156128_bb0210","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Phys Cell Phys"},{"issue":"1","key":"10.1016\/j.metabol.2024.156128_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.metabol.2024.156128_bb0220","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.012730","article-title":"Deletion of fatty acid transport protein 2 (FATP2) in the mouse liver changes the metabolic landscape by increasing the expression of PPAR\u03b1-regulated genes","volume":"295","author":"Perez","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156128_bb0225","doi-asserted-by":"crossref","unstructured":"Chaltel-Lima L, Dom\u00ednguez F, Dom\u00ednguez-Ram\u00edrez L, Cortes-Hernandez P. The Role of the ERRa in Hypoxia and Its Implications for Cancer Metabolism. Vol. 24, International Journal of Molecular Sciences. Apr 28;24(9):7983.","DOI":"10.3390\/ijms24097983"},{"issue":"8","key":"10.1016\/j.metabol.2024.156128_bb0230","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s12015-023-10605-2","article-title":"Estrogen-related receptor alpha (ERR\u03b1) promotes Cancer stem cell-like characteristics in breast Cancer","volume":"19","author":"Muduli","year":"2023","journal-title":"Stem Cell Rev Rep"},{"issue":"2","key":"10.1016\/j.metabol.2024.156128_bb0235","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cgh.2022.01.007","article-title":"Spleen size does not correlate with histological stage of liver disease in people with nonalcoholic fatty liver disease","volume":"21","author":"Cacciottolo","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156128_bb0240","doi-asserted-by":"crossref","first-page":"1197432","DOI":"10.3389\/fcvm.2023.1197432","article-title":"Serum amyloid a and metabolic disease: evidence for a critical role in chronic inflammatory conditions","volume":"10","author":"Den Hartigh","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.metabol.2024.156128_bb0245","doi-asserted-by":"crossref","unstructured":"Sack GH. Serum amyloid A - A review. Vol. 24, Molecular Medicine. 2018. Aug 30;24(1):46.","DOI":"10.1186\/s10020-018-0047-0"},{"key":"10.1016\/j.metabol.2024.156128_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2021.02.124","article-title":"Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD","volume":"555","author":"Li","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.metabol.2024.156128_bb0255","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-016-3970-z","article-title":"Serum amyloid a links endotoxaemia to weight gain and insulin resistance in mice","volume":"59","author":"de Oliveira","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.metabol.2024.156128_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-019-0075-4","article-title":"Silencing of SAA1 inhibits palmitate- or high-fat diet induced insulin resistance through suppression of the NF-\u03baB pathway","volume":"25","author":"Wang","year":"2019","journal-title":"Mol Med"},{"issue":"7","key":"10.1016\/j.metabol.2024.156128_bb0265","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M024463","article-title":"Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids","volume":"53","author":"Houten","year":"2012","journal-title":"J Lipid Res"},{"issue":"20","key":"10.1016\/j.metabol.2024.156128_bb0270","doi-asserted-by":"crossref","first-page":"9079","DOI":"10.1128\/MCB.24.20.9079-9091.2004","article-title":"Estrogen-related receptor \u03b1 directs peroxisome proliferator-activated receptor \u03b1 signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle","volume":"24","author":"Huss","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156128_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/joim.13380","article-title":"Inflammatory and fibrotic mechanisms in NAFLD\u2014implications for new treatment strategies","volume":"291","author":"Lee","year":"2022","journal-title":"J Intern Med"},{"issue":"22","key":"10.1016\/j.metabol.2024.156128_bb0280","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1007\/s00018-020-03549-0","article-title":"Regulation of the expression of the estrogen related receptors (ERRs)","volume":"77","author":"Crevet","year":"2020","journal-title":"Cell Mol Life Sci"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524003561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524003561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:16:18Z","timestamp":1777425378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524003561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":56,"alternative-id":["S0026049524003561"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156128","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.14.618024","asserted-by":"object"}]},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPAR\u03b1-ERR\u03b1 crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156128"}}